The initiation of apoptosis is a core mechanism in cellular biology by which organisms control the removal of damaged or unnecessary cells. The irreversible activation of caspases is essential for apoptosis, and mathematical models have demonstrated that the process is tightly regulated by positive feedback and a bistable switch. BAX and SMAC are often dysregulated in diseases such as cancer or neurodegeneration and are two key regulators that interact with the caspase system generating the apoptotic switch. Here we present a mathematical model of how BAX and SMAC control the apoptotic switch. Formulated as a system of ordinary differential equations, the model summarises experimental and computational evidence form the literature and incorporates the biochemical mechanisms of how BAX and SMAC interact with the components of the caspase system. Using simulations and bifurcation analysis, we find that both BAX and SMAC regulate the time-delay and activation threshold of the apoptotic switch. Interestingly, the model predicted that BAX (not SMAC) controls the amplitude of the apoptotic switch. Cell culture experiments using siRNA mediated BAX and SMAC knockdowns this model prediction. We further validated the model on data of the NCI-60 cell line panel using BAX protein expression as cell-line specific parameter and show that model simulations correlated with the cellular response to DNA damaging drugs and established a defined threshold for caspase activation that could distinguish between sensitive and resistant melanoma cells. In summary, we present an experimentally validated dynamic model that summarises our current knowledge of how BAX and SMAC regulate the bistable properties of irreversible caspase activation during apoptosis.
Introduction
Correct regulation of cellular homeostasis is fundamental in multicellular organisms. Thus, this process is tightly regulated by complex molecular networks which control cell fate, determining when a cell should proliferate, differentiate or die through programmed cell death. Apoptosis is an essential form of programmed cell death which mediates the removal of damaged or unnecessary cells. Tight regulation of apoptosis is vital to the maintenance of normal cell function. Apoptosis can proceed via the extrinsic pathway, induced by binding of an extracellular ligand to its death receptor, or the intrinsic pathway, activated by a diverse array of cytotoxic stimuli which converge on the outer mitochondrial membrane 1, 2 .
Subsequent release of pro-apoptotic proteins from the mitochondria is regulated by proapoptotic and anti-apoptotic BCL2 proteins 2 . Both apoptotic pathways are mediated by the cleaving proteins, caspases, which are produced as inactive zymogens 3 . Initiator caspases (2, 8, 10, 9) are activated by pro-apoptotic proteins and subsequently cleave and activate executioner caspases (3, 6, 7) which act directly on cell dismantling substrates 2, 3 . Apoptosis is triggered when the caspase cascade is irreversibly activated, and several proteins regulate the correct switching on of this machinery to ensure avoidance of incomplete cell death. Positive and negative regulators of the caspases include the BCL2 family of proteins [4] [5] [6] [7] , the inhibitor of apoptosis (IAP) [8] [9] [10] family and several mitochondrial proteins such as APAF 11 , Cytochrome C (CytC ) 5, 7, 12 and SMAC (Second mitochondria-derived activator of caspases), also called Direct IAP-binding Protein with low pI (DIABLO 5,12-15 , hereto SMAC).
Importantly, dysregulation of apoptosis is common in disease, and is a hallmark of cancer and neurodegenerative diseases 16, 17 .
Given its central role in life, the mechanisms that regulate apoptotic networks are the focus of intensive research. This work has shown that there are several control points which determine the activation of apoptosis upon pro-apoptotic signals 5 . Given the complex dynamics regulating these mechanisms, several groups have applied systems biology approaches to study the mechanistic regulation of these apoptotic networks [18] [19] [20] [21] [22] [23] [24] . It has been shown that the relative stoichiometry of the different proteins, caspase cleavage and protein degradation rates determine the commitment of the apoptotic machinery to cell death. In the case of the intrinsic pathway it has been experimentally and computationally demonstrated that caspase dependent apoptosis is a highly controlled process which exhibits an irreversible, bistable switch [18] [19] [20] 25 . Mathematically, bistability is the coexistence of two stable steady states, allowing for rapid, often irreversible transition between these steady states. Once a stimulus threshold is exceeded, the system can switch from a low level of activation (the 'off' stable steady state) to a high level of activation (the 'on' stable steady state) in an all-or-nothing fashion 20 . Phenomenologically, a bistable switch exhibits two characteristic properties. On the level of the dose-response: the emergence of the hysteresis effect which implies that for the system to switch "on" from one steady state to the other, the input stimulus must exceed a certain threshold. The system will reside in this new steady state, even if the stimulus changes. In order to switch "off" to the preceding steady state, a different, lower stimulus threshold must be reached. The hysteresis effect indicates that the system maintains different on and off thresholds. On the level of the time-course, a characteristic time-delay precedes the rapid switch-like transition to the other stable steady-state. Upon application of the input stimulus, the system remains relatively unchanged in the "off" state for some amount of time before rapidly activating in a snap-like fashion. This time-delay of activation can be increased or decreased by alteration of the stimulus concentration or modification of model components.
The primary mechanism generating bistability in the intrinsic pathway is positive feedback 20 .
This positive feedback is realised by an explicit and implicit feedback loop. Explicitly, upon cleavage and activation of caspase 3 by caspase 9, caspase 3 can in turn cleave and activate caspase 9 20 . In the implicitly hidden feedback loop, IAPs can bind and inhibit all caspases within the cascade. Caspase 3 relieves inhibition of its upstream activator caspase 9 through IAP binding, thereby creating a second, implicit positive feedback loop to contribute to the bistability of the system 20 . Previous work indicates that the explicit and implicit feedback mechanisms could be an important feature in determining how the apoptotic system achieves ultra-sensitivity, bistability and irreversibility. In order to get a better understanding of the properties of the bistable switch in the intrinsic apoptotic pathway and understand how its deregulation may be related to disease it is necessary to develop models that include other regulatory proteins of the network. Models developed including BAX and SMAC have shown that these proteins are key in the regulation of apoptotic commitment. BAX is the gateway to mitochondrial activation of intrinsic apoptosis and has been shown to form pores in the mitochondrial membrane resulting in the release of pro-apoptotic proteins [26] [27] [28] . SMAC is one of the proteins released from the mitochondria upon activation of the intrinsic apoptotic pathway and is and inhibitor of IAPs 13 . Correct function of both BAX and SMAC is central to the regulation of apoptosis. Importantly, deregulation of these pro-apoptotic proteins has been described in tumours and patients with neurodegenerative diseases 4, 6, 26, [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] .
Here, we wanted to understand how BAX and SMAC control the emergent properties of the bistable switch. Thus, we have built a mathematical model of BAX and SMAC interactions with the caspase system which mirrors experimental observations from our own experiments and the literature. Here we show that once the caspase 3 activation threshold is reached, caspase 3 switches to the high activity 'on' state in an irreversible, all-or-nothing manner, which is in line with previously published models [18] [19] [20] 22, 43 . We demonstrate that upon increasing the input, BAX expression level or SMAC release rate were shown to reduce the time lag in caspase 3 activation. Our bifurcation analyses revealed that an increase in BAX expression resulted in a reduction in the caspase 3 activation threshold. An increase in SMAC release rate also exhibited a reduction in caspase 3 activation threshold, though to a lesser extent. Simulations confirmed by validation experiments show that the caspase system might be differentially sensitive to BAX and SMAC mimetics. Finally, we further validated the model on data of the NCI-60 cell line panel using BAX protein expression as cell-line specific parameter. The model simulations correlated with the cellular response to DNA damaging drugs, indicating that our model can be used for in silico simulations of pathological changes of the apoptotic machinery.
Results

Model construction:
Dynamic modelling of BAX and SMAC regulated intrinsic apoptotic pathway.
To elucidate how BAX and SMAC regulate the bistable switch within the intrinsic apoptosis pathway, we constructed a mathematical model of Ordinary Differential Equations (ODEs).
To construct the model, we extended the model of caspase activation by Legewie et al. 20 with information from the literature to include (i) BAX mediated initiation of the caspase cascade and (ii) SMAC-mediated sequestration of IAP [44] [45] [46] . The reaction kinetic scheme of the model is outlined in Figure 1 . The expansion of the model to include BAX and SMAC is detailed below.
In the Legewie model, caspase activation is initiated by apoptosome (denoted A* in the model, Figure 1 ) formation through heptamerisation of APAF-1 and binding to procaspase 9 resulting in procaspase 9 autoproteolysis and activation. Active procaspase 9 (C9) then causes caspase 9 (C9*) cleavage and activation. Data has shown that auto-proteolysis of C9 does not impact its recruitment to A* 47, 48 , and so, it has been assumed that A* can recruit and stimulate both C9 and C9*. C9* will activate procaspase 3 (C3) which can in turn cleave and activate caspase 3 (C3*) to act directly on cell dismantling substrates resulting in cell death. C3* can activate caspase 9 through a positive feedback loop. IAP (X), which maintains an E3 ligase domain, can reversibly bind and inhibit all forms of caspase 9 and caspase 3 15 to prevent the activation of cell death.
A limitation of this model is that it does not consider evidence that shows that Cytochrome C (CytC ) release from the mitochondria is dependent on BAX pore formation 7 and further that CytC release itself is insufficient to completely prevent the IAP's inhibitory effect upon caspases which requires the participation of SMAC 49 . Thus, the model was expanded to include apoptotic regulators, BAX and SMAC. BAX becomes activated (BAX*) by a proapoptotic insult (u). To keep the model simple the depolarisation of the mitochondrial membrane by BAX, the release of CytC from the mitochondria and the subsequent activation of APAF-1 causing formation of the apoptosome (A*), was lumped into a single reaction in which A* formation is dependent on active BAX. Concomitantly, SMAC is released from the mitochondria in a BAX* dependant manner to bind and form an inhibitory complex with IAP, which can be degraded 14, 50 . More details about the modelling of BAX and SMAC are provided in two dedicated sections below.
A full account of all reactions, rate laws, parameters and equations, including initial conditions is given in Tables 1 and 2 . This ODE model provides a mathematical representation to describe exactly how a pro-apoptotic insult activates the intrinsic apoptosis pathway and how these species change over time. The model can be used to simulate how cell-line and patient-specific differences of gene and protein expression may alter the system dynamics of caspase activation -predictions which may be experimentally validated.
In the following section we review experimental evidence for the BAX and SMAC mechanisms of crosstalk with the intrinsic apoptosis pathway in detail and show how they are implemented in the dynamic model. Finally, we explore the intricate kinetic behaviour and dynamics of BAX and SMAC-regulated caspase activation.
Modelling BAX
As already mentioned, as one of the most important proteins in the BCL2 pro-apoptotic family, BAX mediates the activation of intrinsic apoptosis in response to DNA damage 51 .Upon pro-apoptotic insult, BAX is translocated to the mitochondrial membrane where it can homo-oligomerise to form the 'apoptotic pore' within the membrane 52 . This In our model BAX acts upstream of APAF-1 heptamerisation ( Figure 1 ). BAX activation and translocation are modelled in a single reaction (reaction v1, Figure 1 ). Neglecting biological details such as the inhibitory binding and neutralisation of BCL-XL to BAX 7,37 , deactivation of BAX* is modelled as a simple first order reaction (v2, Figure 1 ). Active BAX* subsequently mediates the formation of the apoptosome, which is modelled as a first order reaction, dependant on BAX* (v3, Figure 1 ). A*subsequently triggers the activation of the caspase cascade.
Modelling SMAC
Following a pro-apoptotic insult and initiation of MOMP by the BAX mediated formation of pores in the mitochondrial membrane, SMAC is released from the mitochondria into the cytosol, where it binds and releases the inhibitory effect of IAP on caspases 13 . When SMAC binds the second or third BIR domain of IAP, its E3 ubiquitin ligase activity is stimulated, IAP is ubiquitinated and inhibited 53 . Degradation of IAP proteins following SMAC binding results in the loss of its inhibitory effect over procaspases 3 and 9 50 . In this way, SMAC induces the activation of procaspase 3 and mature caspase 3, thus promoting the induction of apoptosis 13 . Early evidence has shown that SMAC can exist as a dimer or monomer and that the dimer is essential for its pro-apoptotic role 13 . It was also shown that the N-terminal region of SMAC is necessary for the activation of caspase 3 and that a short peptide mimicking the N-terminus could mediate activation of apoptosis 13, 49 , demonstrating the key role of this protein in the activation of the intrinsic apoptotic pathway. This has led to the development of a series of SMAC mimetics for the treatment of cancer that are being tested in the clinic 54 .
Based on this knowledge, and to include SMAC, we extended the core model by several processes. BAX* translocation to the mitochondria triggers MOMP-mediated SMAC release and dimerisation. To simplify the model, SMAC release and dimerisation was modelled as a single, first order reaction dependant on BAX* (v19, Figure1). Secondly, SMAC forms a complex with IAP to eliminate IAP inhibition of caspase activity (v20), relieving formation of inhibitory complexes with caspase 9 and caspase 3 (C9IAP, C9*IAP, A*C9IAP, A*C9*IAP, C3*IAP). We have considered SMACIAP complex formation to be a reversible reaction (v21). Degradation of the SMACIAP complex is represented by v22. We have made two assumptions in the modelling of SMAC dynamics. Firstly, we have assumed that the parameter values for SMAC release are similar to those of BAX dependant activation of A* as both are dependent on BAX mediated MOMP. Although, we have assumed SMAC release is 10 times faster than BAX activation of A* formation, to capture the extra time required for the multi-step mechanism of A* formation that was simplified in the model. Secondly, we have assumed that the parameter values for SMAC association with IAP are similar to the caspase-IAP interactions considering they bind at the same site 20 . Though, to ensure that SMAC has the ability to sequester IAP away from both caspase 3 and caspase 9 as has been 1 0 experimentally observed 46 , we have modelled SMAC-IAP binding with slightly higher affinity. Apoptosis is generally considered to be irreversible once the executioner caspase 3 is activated beyond a certain threshold 55 , although it must be noted that recent evidence points to the reversibility of apoptosis in some cases 56 . Once caspase 3 is activated apoptosis can happen in a few minutes 57 . For this reason ,we wanted to double check the irreversibility of the caspase-activation switch in our model 58 . We carried out a simulation study with differently sized pulse stimulations. Transient pulse stimulations with an amplitude of u=0.5nM and durations ranging 300s to 350s were used ( Figure 2B ). In the model, continuous stimulation of u=0.5nM activates C3* at 1500s. Transient pulse stimulation for 310s (u=0.5nM) does not result in activation of C3*. But when u=0.5nM is applied for 315s, C3* activation switches on to reach ~50% of C3* the activation level for continuous stimulation. Increasing lengths of stimulus pulses (320-350s) increases the C3* activation level. Transient pulse activation of the system results in a lower C3* activation level when 1 compared to the nominal model. However, it is important to note that once the C3* activation threshold of 315s (~5mins) stimulation by u=0.5nM is reached, C3* activation is irreversible.
These results demonstrate that the model that we have developed reflects the experimental observations that apoptosis is irreversible once the activation threshold of caspase 3 is reached. Moreover, they also demonstrate that as shown experimentally 57 , caspase activation is regulated by the duration ( Figure 2B ) and strength ( Figure 4A ) of the pro-apoptotic signal.
The model exhibits bistability
The Legewie model showed that IAPs were mediators of positive feedback causing bistability 20 . This and other models have shown that bistability is a key aspect in the regulation of biological networks and in particular is important for the determination of the irreversibility of apoptosis 20 . Therefore, we next wanted to investigate if the addition of BAX and SMAC to our model influenced the bistability and hysteresis previously demonstrated by the Legewie model. To confirm that the model exhibits bistable behaviour we performed a bifurcation analysis. Figure 3A shows two stable (solid line) and one unstable (dashed line) steady states. The system can reside in one of the two stable steady states ('on' or 'off') but not in the intermediate unstable steady state. In this case, the system remains at low caspase 3 activity ('off' state) for increasing stimuli until a threshold of stimulus concentration is reached, at which point caspase 3 activity switches to the second steady state ('on' state)
irreversibly, in an all-or-none fashion. Critically, in line with time course simulations and literature findings 59, 60 , the second bifurcation point of the system is negative( Figure 3B ), which indicates that the activation of C3* is not reversible considering that it is not possible to have negative stimulus concentration. Depending on the state in which the system starts ('on' or 'off' state), differential response curves will be obtained 20 . Importantly, the first bifurcation point at u=0.06nM and the second at u=-0.01nM, indicate that the system displays hysteresis between stimulus concentrations of -0.01 to 0.06nM ( Figure 3 ). This is in line with experimental observations which have shown that apoptosis activation depends on the intensity of the stimulus, allowing the cell to survive if the signal is not sufficient to drive the cell to begin programmed cell death 56 .
Bax and Smac regulate the timing of the apoptotic switch
The previous simulation demonstrated that the model that we have built recapitulates the in vivo behaviour of the intrinsic apoptosis pathway. Therefore, we were confident that this model could be used to study the influence of the pro-apoptotic regulators, BAX and SMAC on the mechanistic properties of the activation of the caspase cascade. Hence, we used simulations to investigate how BAX and SMAC control the timing of the apoptotic switch.
We first investigated how the strength of the input stimulus (intensity of the signal) controls 
Bax and Smac regulate the threshold and amplitude of the apoptotic switch
The results so far indicate that the model that we have generated reflects the behaviour of the intrinsic apoptotic pathway and therefore can be used to analyse the relative contributions of BAX and SMAC to the irreversible activation of the system. Importantly, these proteins have been shown to be deregulated in several diseases such as cancer and neurodegeneration, where incorrect activation of apoptosis are hallmarks 4, 6, 26, [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] . In the case of tumour cells, it has been shown that there is an increase of the threshold of apoptosis activation by downregulation of BAX and SMAC 16, 31, 35 . In neurodegeneration there is an improper activation of apoptosis that has been associated to increased levels of these regulatory proteins 39, 40, 61 . Thus, we posit our model could predict how alterations on BAX and SMAC levels can affect the intrinsic apoptosis pathway in these pathological conditions. To investigate at which precise values transition between stable steady states occur, indicating the threshold of caspase activation, we created bifurcation diagrams for differential concentrations of BAX and SMAC.
First, we investigated how changes in BAX concentration affect the system by performing bifurcation analysis with differential BAX levels. A range of bifurcation plots for differential BAX conditions (BAX0 = 0.1nM-1nM) is shown in Figure 5A . The first limit bifurcation point of the model with BAX0 at 0.5nM occurs at u=0.068nM, where the system transitions from the 'off' state to the 'on' state of C3* activity in an all-or-none fashion. With alteration in BAX0, differential system behaviour emerges. Upon decrease of BAX0, in a similar manner to what can be observed in cancer cells such as melanoma and colorectal cancer 6,28,34,36 , a higher limit bifurcation point is observed (u =0.6nM at BAX0=0.1nM). This shift in bifurcation point indicates an increase in threshold stimulus (u) required for activation of C3* activity upon decrease in BAX0. Conversely, with increase in BAX0 to 0.8nM, a decrease in threshold of C3* activation is observed with a reduced bifurcation point of u=0.04nM. This indicates that with a higher BAX0, there is a reduction in the required stimulus to reach the threshold of activation of C3* and can explain how cell death could be triggered at a lower drug concentration in pathologies were BAX levels are increased.
Importantly, this is biologically sound considering that an increase in BAX translocation to the mitochondrial membrane will enhance MOMP, CytC release and reduce the stimulus required to activate the caspase cascade 5 .
Next, we investigated how altered SMAC levels impact the transition between 'off' and 'on' C3* states. Figure 5B illustrates the C3* bifurcation plots for a range of SMAC values. The parameter 'k19' in Table 1 is the activation rate for SMAC and was altered over a range (0.05s -1 -0.5s -1 ) to produce different levels of SMAC. BAX0 remained at 0.5nM throughout these simulations. The threshold for activation of C3* with k19=0.1s -1 is u=0.68nM). With decrease in SMAC activation by decreasing k19 to 0.05, the threshold for activation of caspase 3 increases to u=0.98nM indicating the additional stimulus required to activate C3* upon decreased SMAC levels. With increase in SMAC activation, a downward shift in C3* activation threshold to u=0.02nM is observed. This implies that with an increase in SMAC levels, by employing a faster activation rate (k19), a lower input stimulus is required to reach the threshold of activation of C3*.
These simulations demonstrate that our model can be used to predict what happens when alterations to SMAC and BAX levels occur in pathological conditions. Importantly, our simulations also showed that while alteration of BAX and SMAC impact the threshold of activation of C3* in a similar pattern, decrease of BAX0 causes a larger increase in the threshold of C3* activation when compared to a decrease in SMAC activation. This would indicate that BAX, but not SMAC, is a more prominent regulator of the apoptotic switch.
Next, we investigated how BAX and SMAC regulate the amplitude of caspase 3 activation.
The bifurcation diagrams show BAX affected the C3* values of the 'on' state more prominently than the SMAC levels. Further, the 'on' state of caspase 3 saturates at high input concentrations (u>0.5nM). To analyse more quantitatively how alteration of BAX and SMAC impact this saturation amplitude of caspase 3 activation, we simulated dose responses for increasing input concentrations and different BAX and SMAC levels. Firstly, varying the BAX expression levels 5-fold down and up (0.1 -1 nM) caused variations in the C3* amplitude from 120 to 180 nM (Supplementary Figure 1A) . Note that for lower BAX level (<0.1) the activation threshold shifts to unphysiological high input concentrations and C3* does not activate. Secondly, varying the SMAC release rate over a 10-fold range (k19, 0.05 -0.5 s -1 ) only caused variations in the C3* amplitude from 160 to 180 nM (Supplementary Figure 1B) . Note that decreasing SMAC release rates even lower (<0.05s -1 ) C3* does not affect the ability of the system to switch on, nor does it change the C3* amplitudes. Thus, our model predicts that the amplitude of caspase 3 activation is more sensitive to changes in BAX than to changes in SMAC.
Finally, to get a further characterisation of the role of BAX and SMAC in the system we decided to investigate whether alteration of BAX or SMAC impacted the irreversibility of the switch. We studied the second bifurcation point of the system where C3* is transitioning from the high activity 'on' state to the 'off' state. We observed that alteration of BAX and SMAC does not impact the irreversibility of C3* activation. Although the second bifurcation point increased with increased BAX0 and SMAC, it never became positive indicating that the activation of C3* remains irreversible. Thus, BAX and SMAC do not impact the existence of bistability in our model. In line with other observations in the literature 21 , our results demonstrate that the main function of BAX and SMAC is to control the quantitative bistable properties (such as the "on" state threshold and amplitude), not to generate bistability itself. Bistability of our system emerges as a result of implicit and explicit feedback loops, as in line with the literature [19] [20] [21] .
Validation experiments confirm that caspase activation is more sensitive to BAX than SMAC
We performed experiments to validate the most salient model prediction; that alteration of BAX and SMAC expression levels impact the bistable properties of caspase activation. As outlined above, model simulations suggest that the amplitude of caspase activation can be impacted by alteration of BAX, and to a lesser extent SMAC, expression levels. To experimentally validate these model predictions and confirm the role that BAX and SMAC play in controlling the caspase 3 activation, we performed cell culture experiments. In these experiments, reduction of either BAX or SMAC level was achieved by RNA interference (siRNA) and intrinsic apoptosis was induced by the DNA damaging agent Etoposide (50µM for~18 hours). To confirm that the downregulation of BAX and SMAC worked, their protein expression levels were measured by western blot (Figure 6A ). Western blot also demonstrated that upon Etoposide treatment, an increase in BAX protein levels are observed, independently of SMAC levels. This increase in BAX protein levels indicate the induction of BAX upon DNA damage to translocate to the mitochondria and initiate the intrinsic caspase cascade.
The corresponding total caspase activity was measured by flow cytometry and is shown in 
Simulated Caspase Activation Correlates with Drug Sensitivity in a Panel of Melanoma Cell Lines
To further experimentally validate our model, we next tested whether our model could explain the drug-responses of different cell lines. To do this, we analysed publicly available NCI-60 datasets for which proteomic-profiling and drug-response data were available and used the protein expression information to perform cell line specific simulations. These datasets consist of 60 cell lines from 9 tissues, mass-spectrometry based proteome measurements, and measured drug response scores for more than 100,000 drugs, including etoposide 62, 63 . BAX but not SMAC levels correlated with etoposide response, Pearson correlation coefficient (C) = 0.307, p-value (p) =0.019, (Suppl Fig. 3 ), suggesting that BAX but not SMAC protein levels provide useful information to personalize the model to the individual cell lines. Thus, we focused on BAX to generate cell-line specific simulations. The measured SWATH values for BAX were used to adjust the BAX total protein expression parameter in the model as follows; if for example BAX levels were 1.5 times increased in cell line A, then we increased the corresponding BAX protein expression parameter (k1) by a factor of 1.5. The resulting set of cell-line specific parameters was then used to simulate the caspase activation trajectories for each cell line.
The simulation results showed that the C3 amplitude and activation-threshold varied markedly between cell-lines (ranging from 120 to almost 180 nM, Fig 7A, B) and correlated with the etoposide response (C=0.3, p-value=0.022, Fig 7C) . This correlation between the C3 amplitude and the etoposide response might be a tissue effect, meaning that one tissue is sensitive to etoposide, but another is not. To check this, we looked at the variability of the simulated responses across tissues but observed no pronounced differences of the C3 amplitude between different tissues (Fig. 7A ). This indicates that the observed correlation between the C3 amplitude and the etoposide response depends on the specific genomics of each cell-line and not tissue-specific differences.
Another explanation for the correlation might be that model explains the etoposide response very well in one tissue but not the others. To test this, we analysed the simulations for each tissue separately, focusing on those tissues with more than 5 cell lines ( Table 3 ). The best correlation between the simulated C3 amplitude and the etoposide response was observed in melanoma cell lines, C=0.855, pval =0.003, n=9 cell-lines ( Fig 7D) . To confirm this, we also analysed data from an independent drug screen (GDSC 64 ), and found a similar correlation C=0.76, pval0.046, n=7 ( Fig 7E) . Ovarian cancer cell lines also exhibited a correlation, C=0.77, pval =,0.04, n=7 ( Fig S3) . The correlations for the other tissues (leukemia, colorectal, CNS, breast, renal, lung and prostate) were weak and not significant ( Table 3) .
Focusing on the melanoma cells, we wanted to test how general the model is with respect to other DNA damaging drugs and analysed the data for bleomycin, cisplatin, and doxorubicin.
For all three drugs, the drug response scores correlated with the simulated C3 amplitude ( Fig   S3) . The correlation of the C3 amplitude with the bleomycin and doxorubicin responses was particularly strong and significant (C=0.77, pval=0.03 and C=0.79, pval=0.02, respectively).
The results suggest that the model can be used to simulate and predict caspase activation and the responses to DNA damaging drugs in melanoma cells.
Given the observed correlation between the simulated C3 amplitude and the response to DNA damaging drugs, we asked whether a particular threshold in the model could distinguish between sensitive and resistant cells. We found that for all analysed drugs, a threshold value for the C3 amplitude of 163 nM was able to distinguish between sensitive and resistant cells ( Fig. 7F ). All melanoma cells with a simulated C3 amplitude less than 163 nM were sensitive 1 9 to etoposide, bleomycin, cisplatin and doxorubicin, with NCI-60 response scores < 0 (n=8 cells). Conversely, the cell lines with a simulated C3 amplitude greater that 163 nM were resistant to all three drugs. Only one outlier for doxorubicin was observed, where M14, was falsely classified as sensitive (Fig. 7F) . In summary, our results suggest that BAX protein levels can be used to personalize the model, simulate caspase activation, and predict drugresponses for DNA-damaging drugs in melanoma cells. A defined threshold value of 163 nM of caspase activation in the model distinguishes between sensitive and resistant melanoma cells.
Discussion
In the current work we have developed a mathematical model of the intrinsic apoptotic pathway that recapitulates the behaviour of this systems in cells. The current model includes BAX and SMAC, two nodes that have not been widely analysed in previous computational models but are bona fide regulators of this network. Importantly, the addition of these nodes in the model and their experimental is a clear advance of our study with respect to other models, and better recapitulates the behaviour of the system in cells and the enhances the Importantly, our model confirms the existence of bistability in accordance with other studies of the apoptosis network 20, 21 . However, many studies modelling apoptosis focused on the extrinsic pathway consisting of death receptor activation, subsequent activation of caspases and secondary activation of the mitochondrial pathway 22, 23, 67, 68 , or the processes upstream of caspase activation such as BCL2 protein regulation of MOMP [21] [22] [23] 69, 70 . Other modelling studies that concerned the activation of caspases in the intrinsic pathway did either not look at the control of bistable properties 22, 67, 69 , or did not include BAX and SMAC 19, 20, 23 . A notable exception is the work by Tyson and colleagues 21 , which provided and excellent account of which network nodes and parameters regulate the bistability properties, in particular 1 irreversibility, time-delay and threshold. They found that the time-delay and threshold are primarily controlled by the initiator module (corresponding to BAX in our model), which is in accordance with our findings. However, we also find that SMAC, which merely relayed the signal in the Tyson model, markedly controlled the delay and threshold of caspase activation. Further, and in contrast to Tyson, we also analysed how BAX and SMAC control the amplitude of the apoptotic switch, and experimentally validated this prediction.
The results from our simulations clearly indicate that the modification of BAX and SMAC levels have a direct effect in the threshold and time delay of caspase 3 activation and determine when the system reaches the point of no return. Thus, the simulation shows that decrease of both proteins results in an increase of this threshold of apoptosis, i.e. lowering the expression of these proteins makes the system more resistant to pro-apoptotic stimuli. Therefore, at low level of expression of BAX, our model mimics the cellular state of tumours where the loss of BAX expression is a common feature. Conversely, high level of expression BAX would resemble other diseases were aberrant activation of apoptosis is part of the pathology. For instance, increases in BAX level have been associated with the activation of programmed cell death in degenerative diseases, especially neurodegeneration, and other diseases such as ischemia and heart infarction 71, 72 . With respect to SMAC, similar observations are shown in the same diseases 4, 38, 39, 41, 50, [73] [74] [75] [76] [77] [78] [79] [80] [81] . For these reasons, our bifurcation analysis can be considered as simulations of what would happen to the whole system in physiological and pathological conditions. The fact that the personalised simulations of caspase 3 activity correlated with the response to DNA damaging drugs in the NCI-60 pan cancer dataset suggests that the model can be used to predict the individual cellular responses of different cell lines and patients. This could work particularly well for melanoma, where the cell-line specific simulations confirmed the existence of a distinct threshold separating sensitive from resistant melanoma cells. To improve the model for other tissues, further key nodes that regulate the caspase system in addition to BAX could be tested, mathematically modelled, and connected to the current model. Prime candidates are members of the BCL2 family and a more detailed model of the outer mitochondria membrane permeabilization that have proven predictive power in triple negative breast and colorectal cancer 44, 82, 83 .
Personalising this model with experimental and clinical data could be used to carry out in silico drug targeting and could help the development of novel therapeutics for apoptosisdependent diseases. Importantly, our simulations indicate that critical bistable properties such as the amplitude of the "on-state" are more dependent on variations of the level of BAX than SMAC. Taking into account that there are currently different SMAC and BAX mimetics for the treatment of cancer at different stages of development, our model would support the idea that BAX mimetics would be more effective than SMAC mimetics. In the context of regenerative therapies that aim to preventing excessive apoptosis, our finding might indicate that targeting BAX translocation could be more efficient than targeting SMAC.
In summary we present a new experimentally validated mathematical model that can be used to study the dynamics of activation of apoptosis by the mitochondrial pathway.
Materials and Methods
Model Construction and Simulation
Our core model is based on a well-established model of caspase bistability in the literature 20 and has been extended to include BAX and SMAC and the associated reactions (see main text, Fig. 1 ). Based on this reaction kinetic scheme an ODE model has been constructed using the principle of mass balance and the appropriate reaction kinetic laws, as is common practice 84 . All ODE simulations were carried out using the MATLAB environment (R2018a).
Bifurcation analyses were carried out using XPPAUT (http://www.math.pitt.edu/~bard/bardware/xpp/xpp.html) and plotted using the plotxppaut plugin for MATLAB(http://www2.gsu.edu/~matrhc/XPP-Matlab.html).
Cell culture
HeLa cells (ATTC) were grown in DMEM (Gibco) supplemented with 10% FBS (Gibco) and 
Caspase activation assay
Caspase activation was measured in an Accuri's C6 Flow Cytometer System using the CaspACE-FITC-VAD-FMK kit (Promega). Alive and dead cells were collected, centrifuged for 5 minutes at 300xg and incubated with FITC-VAV-FMK in serum free media (1:2000) for 30 minutes at 37˚C protected from light. Cells were washed once with PBS and incubated with PI for 5 minutes at room temperature prior to acquisition. FITC and PI emissions were measured using the 533/30 and 670LP detectors respectively following excitation by 488nm laser. Statistical analysis was carried out to determine the mean caspase activation and standard deviation within each group (siNT, siBAX and siSMAC), control and treated. Fold change in caspase activation was calculated for each treated group compared to the group control.
Western Blot
Cells were lysed in a buffer containing: 20 mM Hepes pH 7.5, 150 mM NaCl, 1 % NP40 supplemented with protease and phosphatase inhibitors (Roche). Protein extracts were clarified by centrifugation (14,000 rpm, 4˚C, 10 minutes) and pellet discarded. Protein quantification was carried out using the BCA protein Assay kit (23225-Invitrogen) according to manufacturer's protocol. Primary antibodies (1:1000 dilution): anti-SMAC Y12 (ab32023-Abcam), anti-BAX 6A7 (556467-BD Pharmingen), Tubulin TU-U2 (sc-8035-Santa Cruz). 
Cell Line Specific Simulations
